Evidence map›Paper›PMID 26490315›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2016

Fluorescent Image-Guided Surgery with an Anti-Prostate Stem Cell Antigen (PSCA) Diabody Enables Targeted Resection of Mouse Prostate Cancer Xenografts in Real Time.

Geoffrey A Sonn, Andrew S Behesnilian, Ziyue Karen Jiang, Kirstin A Zettlitz, Eric J Lepin, Laurent A Bentolila, Scott M Knowles, Daniel Lawrence, Anna M Wu, Robert E Reiter

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 44 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. [Molecular imaging and biology · 2020
    Article
  10. Article
  11. Article
  12. On-demand radiosynthesis ofRSC advances · 2019
    Article
  13. A Dual-Modality Linker Enables Site-Specific Conjugation of Antibody Fragments forJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019
    Article
  14. A Fluorescent, [ACS chemical biology · 2019
    Article
  15. Specific Targeting of Somatostatin Receptor Subtype-2 for Fluorescence-Guided Surgery.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019
    Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Geoffrey A SonnDepartment of Urology, University of California, Los Angeles, California.
Andrew S BehesnilianDepartment of Urology, University of California, Los Angeles, California.
Ziyue Karen JiangDepartment of Urology, University of California, Los Angeles, California.
Kirstin A ZettlitzMolecular and Medical Pharmacology, University of California, Los Angeles, California. Crump Institute for Molecular Imaging, University of California, Los Angeles, California.
Eric J LepinMolecular and Medical Pharmacology, University of California, Los Angeles, California. Crump Institute for Molecular Imaging, University of California, Los Angeles, California.
Laurent A BentolilaDeparment of Chemistry and Biochemistry, University of California, Los Angeles, California. California NanoSystems Institute, University of California, Los Angeles, California.
Scott M KnowlesMolecular and Medical Pharmacology, University of California, Los Angeles, California. Crump Institute for Molecular Imaging, University of California, Los Angeles, California.
Daniel LawrenceMolecular and Medical Pharmacology, University of California, Los Angeles, California.
Anna M WuMolecular and Medical Pharmacology, University of California, Los Angeles, California. Crump Institute for Molecular Imaging, University of California, Los Angeles, California.
Robert E ReiterDepartment of Urology, University of California, Los Angeles, California. Rreiter@mednet.ucla.edu.
Los Angeles Medical Center · USUniversity of California, Los Angeles · USCalifornia NanoSystems Institute · US

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
UCLA SPORE IN PROSTATE CANCERP50CA092131 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI FREEMAN, MICHAEL R · 2002 to 2023
$42.6M
Multifunctional immunoPET tracers for pancreatic and prostate cancerR01CA174294 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI REITER, ROBERT E, WU, ANNA M · 2013 to 2020
$3.3M
NCI NIH HHS P30 CA016042NCI NIH HHS P50 CA092131NCI NIH HHS P50CA092131NCI NIH HHS R01 CA174294NCI NIH HHS R01CA174294
6 · The paper itself

Abstract

purposeThe inability to visualize cancer during prostatectomy contributes to positive margins, cancer recurrence, and surgical side effects. A molecularly targeted fluorescent probe offers the potential for real-time intraoperative imaging. The goal of this study was to develop a probe for image-guided prostate cancer surgery. EXPERIMENTAL

designAn antibody fragment (cys-diabody, cDb) against prostate stem cell antigen (PSCA) was conjugated to a far-red fluorophore, Cy5. The integrity and binding of the probe to PSCA was confirmed by gel electrophoresis, size exclusion, and flow cytometry, respectively. Subcutaneous models of PSCA-expressing xenografts were used to assess the biodistribution and in vivo kinetics, whereas an invasive intramuscular model was utilized to explore the performance of Cy5-cDb-mediated fluorescence guidance in representative surgical scenarios. Finally, a prospective, randomized study comparing surgical resection with and without fluorescent guidance was performed to determine whether this probe could reduce the incidence of positive margins.

resultsCy5-cDb demonstrated excellent purity, stability, and specific binding to PSCA. In vivo imaging showed maximal signal-to-background ratios at 6 hours. In mice carrying PSCA(+) and negative (-) dual xenografts, the mean fluorescence ratio of PSCA(+/-) tumors was 4.4:1. In surgical resection experiments, residual tumors <1 mm that were missed on white light surgery were identified and resected using fluorescence guidance, which reduced the incidence of positive surgical margins (0/8) compared with white light surgery alone (7/7).

conclusionsFluorescently labeled cDb enables real-time in vivo imaging of prostate cancer xenografts in mice, and facilitates more complete tumor removal than conventional white light surgery alone.

Indexed as

Surgery, Computer-AssistedAnimalsAntibodies, MonoclonalAntigens, NeoplasmDisease Models, AnimalFluorescent DyesGPI-Linked ProteinsHumansImmunoglobulin FragmentsMaleMiceNeoplasm ProteinsOptical ImagingProstatic NeoplasmsXenograft Model Antitumor AssaysAntibodies, MonoclonalAntigens, NeoplasmFluorescent DyesGPI-Linked ProteinsImmunoglobulin FragmentsNeoplasm ProteinsPSCA protein, human

Identifiers

PMID26490315
PMCPMC4794340
OpenAlexW2191207157

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.